HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Atypical Mycobacterium Infections

Subscribe to New Research on Atypical Mycobacterium Infections

Infections with so called atypical mycobacteria (tuberculoid bacilli): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae.

Also Known As:

Mycobacterium Infections, Atypical; Atypical Mycobacterial Infection, Disseminated; Atypical Mycobacteriosis, Familial; Atypical Mycobacteriosis, Familial Disseminated; Infections, Atypical Mycobacterium; Infections, Tuberculoid; Atypical Mycobacterioses, Familial; Atypical Mycobacterium Infection; Familial Atypical Mycobacterioses; Familial Atypical Mycobacteriosis; Infection, Atypical Mycobacterium; Infection, Tuberculoid; Mycobacterioses, Familial Atypical; Mycobacteriosis, Familial Atypical; Mycobacterium Infection, Atypical; Tuberculoid Infection; Tuberculoid Infections

Networked: 12 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses
- Bacterial Infections: 10283
  - Gram-Positive Bacterial Infections: 158
    - Actinomycetales Infections: 1
      - Mycobacterium Infections: 56
        Atypical Mycobacterium Infections: 12
        Buruli Ulcer: 159
        Infection with Mycobacterium marinum: 73
        Mycobacterium avium-intracellulare Infection: 52
        Mendelian susceptibility to Mycobacterial disease: 15

Related Diseases

1.	Viremia
2.	Lymphoma (Lymphomas)
3.	Infection
4.	Paucibacillary Leprosy
5.	Leprosy (Hansen's Disease)

Experts

1.	Viljoen, Joe: 1 article (12/2015)
2.	du Plessis, Jeanetta: 1 article (12/2015)
3.	van Zyl, Lindi: 1 article (12/2015)
4.	Tanase, Ursula: 1 article (01/2015)
5.	Heinz, Werner J: 1 article (01/2015)
6.	Klinker, Hartwig Hf: 1 article (01/2015)
7.	Schwerdtfeger, Christiane: 1 article (01/2015)
8.	Von Figura, Guido: 1 article (01/2015)
9.	Thies, Philipp: 1 article (01/2015)
10.	Wille, Florian: 1 article (01/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Atypical Mycobacterium Infections:

1.	IntegrasesIBA 01/01/2015 - "While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. "
2.	Tuberculin (PPD)IBA 02/01/1986 - "[Identification of atypical mycobacterium infections by PPD-B skin tests]."
3.	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 04/01/1967 - "Group IV atypical mycobacterium infection occurring in association with mineral oil granuloma of lungs."
4.	AntigensIBA 01/01/1992 - "Sera from 77 leprosy patients in various stages of infection--tuberculoid (TT), lepromatous (LL), borderline tuberculoid and borderline lepromatous--15 contacts and 21 normal healthy individuals, were assayed in an indirect enzyme-linked immunosorbent assay and dot enzyme immunoassay using ethanol-soluble and thermostable extract of liver as the antigen. "
5.	EpitopesIBA 07/01/1981 - "Atypical mycobacterium infection treated with dialyzable leukocyte extracts: evidence for antigenic specificity."
6.	Anti-Bacterial Agents (Antibiotics)IBA 12/01/2015 - "Atypical mycobacterium infections are mostly resistant to anti-tuberculous drugs and only respond to certain antibiotics. "
7.	Ethanol (Ethyl Alcohol)IBA 01/01/1992 - "Sera from 77 leprosy patients in various stages of infection--tuberculoid (TT), lepromatous (LL), borderline tuberculoid and borderline lepromatous--15 contacts and 21 normal healthy individuals, were assayed in an indirect enzyme-linked immunosorbent assay and dot enzyme immunoassay using ethanol-soluble and thermostable extract of liver as the antigen. "
8.	MK 0518 FDA Link 01/01/2015 - "While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. "
9.	sulfolipid IIBA 06/01/2000 - "Sulfolipid-I (SL-I) is a specific Mycobacterium tuberculosis glycolipid that has been involved in the mechanisms of tuberculoid infection. "

Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART) 12/01/1998 - "VARIABLE RESULTS: The restoration of immunological competence following Highly Active AntiRetroviral Therapy (HAART) has led to promising results concerning cytomegalovirus viremia, atypical mycobacterium infections, and survival in patients treated for non-Hodgkin's lymphomas. "
2.	Arthroplasty 08/01/2005 - "Atypical mycobacterium infection after total hip arthroplasty is a very rare but a potential cause of implant failure. " 01/01/1996 - "When infection following total knee arthroplasty is evident but standard cultures come back negative, atypical mycobacterium infection should be considered. " 08/01/2005 - "Although the treatment of atypical mycobacterium infection after total hip arthroplasty is controversial, we successfully treated the infection in this case, after consultation with a microbiologist regarding infection management, with both surgery and chemotherapy. "
3.	Prostheses and Implants (Prosthesis) 08/01/2005 - "It is important to maintain a high index of suspicion for atypical mycobacterium infection, particularly when standard culture findings are negative despite strong clinical evidence of prosthesis infection."
4.	Transplantation (Transplant Recipients) 01/01/1999 - "Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient."
5.	Drug Therapy (Chemotherapy) 08/01/2005 - "Although the treatment of atypical mycobacterium infection after total hip arthroplasty is controversial, we successfully treated the infection in this case, after consultation with a microbiologist regarding infection management, with both surgery and chemotherapy. "